2022 World Conference on Lung Cancer (ePosters)-EP16.03-023. KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients

EP16.03-023. KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients

Back to course

Pdf Summary

Genetic profiling and next-generation sequencing have revolutionized the understanding and treatment of non-small cell lung cancer (NSCLC), particularly adenocarcinoma. The prevalence and clinical significance of the KRAS mutation in NSCLC patients from Mexico were assessed in this study. A total of 313 NSCLC patients were analyzed, with a median age of 61 years. Most patients were female, non-smokers, and diagnosed with stage IV disease. The most common sites of metastasis included bone, lung, pleural, lymph nodes, and central nervous system. The frequency of KRAS mutation in these patients was 15.4%, with the most common subtypes being G12C, G12D, and G12V. The G12C subgroup had a higher association with central nervous system metastasis and smoking history. No significant associations were found between KRAS status and other clinicopathological features. Co-occurring mutations were also observed, including TP53, CDKN2A, GNAS, STK11, and PIK3CA.<br /><br />The median overall survival for patients with KRAS mutation was 12.6 months. Patients with KRAS G12C subtype had a trend towards longer overall survival compared to non-G12C subtypes. Patients with both KRAS and TP53 mutations also tended to have longer survival. However, no statistically significant difference in overall survival was found between KRAS-mutant and KRAS-wildtype patients. <br /><br />In conclusion, this study revealed a lower frequency of KRAS mutation in NSCLC patients from Mexico compared to other populations. Furthermore, KRAS-mutant NSCLC was found to be a heterogeneous subgroup with varying clinical characteristics and co-occurring mutations. The clinical impact of these co-occurring mutations requires further investigation. There is still a need for effective therapies for patients with KRAS-mutant NSCLC.

Asset Subtitle

Maritza Ramos-Ramirez

Meta Tag

Speaker Maritza Ramos-Ramirez

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

genetic profiling

next-generation sequencing

non-small cell lung cancer

NSCLC

adenocarcinoma

KRAS mutation

Mexico

metastasis

co-occurring mutations

overall survival